These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25497672)

  • 61. Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.
    Germano A; Rapa I; Duregon E; Votta A; Giorcelli J; Buttigliero C; Scagliotti GV; Volante M; Terzolo M; Papotti M
    Endocr Pathol; 2017 Jun; 28(2):95-102. PubMed ID: 28271381
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Lee JJ; Maeng CH; Baek SK; Kim GY; Yoo JH; Choi CW; Kim YH; Kwak YT; Kim DH; Lee YK; Kim JB; Kim SY
    Lung Cancer; 2010 Nov; 70(2):205-10. PubMed ID: 20223551
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer.
    Feng JF; Wu JZ; Hu SN; Gao CM; Shi MQ; Lu ZH; Sun XC; Zhou JR; Chen BA
    Lung Cancer; 2009 Dec; 66(3):344-9. PubMed ID: 19304340
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adrenal proteins bound by a reactive intermediate of mitotane.
    Cai W; Counsell RE; Schteingart DE; Sinsheimer JE; Vaz AD; Wotring LL
    Cancer Chemother Pharmacol; 1997; 39(6):537-40. PubMed ID: 9118466
    [TBL] [Abstract][Full Text] [Related]  

  • 65. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
    Mauclère-Denost S; Leboulleux S; Borget I; Paci A; Young J; Al Ghuzlan A; Deandreis D; Drouard L; Tabarin A; Chanson P; Schlumberger M; Baudin E
    Eur J Endocrinol; 2012 Feb; 166(2):261-8. PubMed ID: 22048971
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mitotane (o,p'-DDD) resistance in a dog with pituitary-dependent hyperadrenocorticism and phaeochromocytoma.
    Bennett PF; Norman EJ
    Aust Vet J; 1998 Feb; 76(2):101-3. PubMed ID: 9578778
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High (18)F-FDG uptake by the remaining adrenal gland four months after surgery and initiation of mitotane treatment in two patients with adrenocortical carcinoma.
    Mpanaka I; Lyra VD; Kaltsas G; Chatziioannou SN
    Hell J Nucl Med; 2011; 14(2):168-72. PubMed ID: 21761022
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans.
    Nader N; Raverot G; Emptoz-Bonneton A; Déchaud H; Bonnay M; Baudin E; Pugeat M
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2165-70. PubMed ID: 16551731
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.
    Demeure MJ; Stephan E; Sinari S; Mount D; Gately S; Gonzales P; Hostetter G; Komorowski R; Kiefer J; Grant CS; Han H; Von Hoff DD; Bussey KJ
    Ann Surg; 2012 Jan; 255(1):140-6. PubMed ID: 22156929
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.
    Seki M; Nomura K; Hirohara D; Kanazawa M; Sawada T; Takasaki K; Demura H
    Endocr Relat Cancer; 1999 Dec; 6(4):529-33. PubMed ID: 10730906
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
    Chortis V; Taylor AE; Schneider P; Tomlinson JW; Hughes BA; O'Neil DM; Libé R; Allolio B; Bertagna X; Bertherat J; Beuschlein F; Fassnacht M; Karavitaki N; Mannelli M; Mantero F; Opocher G; Porfiri E; Quinkler M; Sherlock M; Terzolo M; Nightingale P; Shackleton CH; Stewart PM; Hahner S; Arlt W
    J Clin Endocrinol Metab; 2013 Jan; 98(1):161-71. PubMed ID: 23162091
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.
    Abiven G; Coste J; Groussin L; Anract P; Tissier F; Legmann P; Dousset B; Bertagna X; Bertherat J
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2650-5. PubMed ID: 16670169
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of the expression of human equilibrative nucleotide transporter 1 (hENT1) and ribonucleotide reductase subunit M1 (RRM1) genes in seven non-Hodgkin lymphoma cell lines.
    Zhao HB; Zhang XF; Shi F; Zhang MZ; Xue WL
    Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173327
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adrenal gland: Cancer target of mitotane identified.
    Holmes D
    Nat Rev Endocrinol; 2015 Nov; 11(11):631. PubMed ID: 26370730
    [No Abstract]   [Full Text] [Related]  

  • 75. Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring.
    Kerkhofs TM; Derijks LJ; Ettaieb MH; Eekhoff EM; Neef C; Gelderblom H; den Hartigh J; Guchelaar HJ; Haak HR
    Eur J Endocrinol; 2014 Dec; 171(6):677-83. PubMed ID: 25201518
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Non-enzymatic action of RRM1 protein upregulates PTEN leading to inhibition of colorectal cancer metastasis.
    Qi H; Lou M; Chen Y; Liu X; Chen N; Shan J; Ling Z; Shen J; Zhu L; Yen Y; Zheng S; Shao J
    Tumour Biol; 2015 Jun; 36(6):4833-42. PubMed ID: 25638032
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Antineoplastic Effect of a Combined Mitotane Treatment/Ionizing Radiation in Adrenocortical Carcinoma: A Preclinical Study.
    Cerquetti L; Bucci B; Carpinelli G; Lardo P; Proietti A; Saporito R; Rindi G; Petrangeli E; Toscano V; Stigliano A
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31717612
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies.
    Lo Iacono M; Puglisi S; Perotti P; Saba L; Petiti J; Giachino C; Reimondo G; Terzolo M
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771418
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy.
    Millis SZ; Ejadi S; Demeure MJ
    Biomark Cancer; 2015; 7():69-76. PubMed ID: 26715866
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Current and emerging therapeutic options in adrenocortical cancer treatment.
    Stigliano A; Cerquetti L; Sampaoli C; Bucci B; Toscano V
    J Oncol; 2012; 2012():408131. PubMed ID: 22934112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.